Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Drug Approval Standards

ANDA Approval Speed-Up Leaves Sponsors With Less Margin For Error

  • News

Executive Summary

Get applications in right, or get a complete response letter, FDA says; firms will have fewer opportunities for mid-review application corrections as review goals reach 10 months.

Table

View full table

Advertisement

Related Content

Pink Sheet
Sentinel May Expand To Generic Equivalence Studies
Pink Sheet
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
Pink Sheet
FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs
Pink Sheet
GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
Pink Sheet
ANDA Approvals, Submissions Decline With New Review Goal Coming
Pink Sheet
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Topics

Advertisement
Tags:
BioPharmaceutical United States Drug Approval Standards
UsernamePublicRestriction

Register

PS057667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By